前列地尔和胰激肽原酶治疗早期糖尿病肾病的疗效观察.docVIP

精品论文 参考文献 前列地尔和胰激肽原酶治疗早期糖尿病肾病的疗效观察 江苏省连云港市第二人民医院内分泌科 江苏 连云港222000 【摘要】目的：探讨前列地尔和胰激肽原酶治疗早期糖尿病肾病的疗效。方法：选取我院自2014年4月份至2015年6月份期间收治的100例早期糖尿病肾病患者作为本次的临床研究对象，并将其进行单双号随机分为对照组和观察组两组，单号为对照组，双号为观察组，每组各有患者50例。其中对照组患者采取胰激肽原酶进行单一治疗，观察组则在对照组的基础上联合前列地尔进行治疗。结果：两组患者治疗后各项指标对比表示：观察组患者的24h尿蛋白排泄量、血肌酐、血尿素氮以及总有效率均较对照组优异（Plt;0.05）。结论：针对早期糖尿病肾病的患者，使用前列地尔联合胰激肽原酶治疗的效果更为显著，且见效快，值得在临床上推广。 【关键词】前列地尔；胰激肽原酶；早期糖尿病肾病 【中图分类号】R587.2【文献标识码】A【文章编号】1001-5213(2016)08-0101-02 Efficacy of alprostadil and pancreatic kallikrein treatment of early diabetic nephropathy 【Abstract】Objective:To investigate alprostadil and pancreatic kallikrein therapeutic efficacy of early diabetic nephropathy. Methods: admitted to our hospital during the period from April 2014 to June 2015 100 cases of early diabetic nephropathy as this clinical study, and odd and even numbers were randomly divided into control group and observation group two, a single number as the control group, the number is double the observation group, 50 patients in each group. Wherein the control patients take pancreatic kallikrein monotherapy, combined with the observation group alprostadil treatment on the basis of the control group. Results: The two groups of patients after treatment indicators contrast, said: observation group patients 24h urinary protein excretion, serum creatinine, blood urea nitrogen and total efficiency superior than the control group (P lt;0.05). Conclusion: For patients with early diabetic nephropathy, effect of alprostadil combined with pancreatic kallikrein treatment is more significant, and effective, and should be promoted in clinical practice. 【Key words】Alprostadil;Pancreatic kallikrein;Early diabetic nephropathy 糖尿病肾病是由糖尿病引起的危害性最大的一种慢性并发症，该病的临床症状常表现为贫血、水肿、蛋白尿、高血压以及肾功能异常等，该病症对患者的生活质量造成了严重的影响，若不能及时采取有效的治疗，严重者将会导致死亡[1-2]。本文就对此进行具体分析。 1 资料和方法 1.1 基线资料 选取在我院接受治疗的100例早期糖尿病肾病患者作为本次的临床研究对象，并将其进行单双号随机分为对照组和观察组2组，其中单号为对照组，双号为观察组，每组各有患者50例。观察组：男27例，女23例；平均年龄为（51.31plusmn;12.56）岁；平均病程为（6.45plus